company background image
SCPX logo

Scorpius Holdings NYSEAM:SCPX Stock Report

Last Price

US$0.16

Market Cap

US$5.9m

7D

-1.9%

1Y

-80.5%

Updated

27 Mar, 2024

Data

Company Financials +

Scorpius Holdings, Inc.

NYSEAM:SCPX Stock Report

Market Cap: US$5.9m

SCPX Stock Overview

Scorpius Holdings Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization.

SCPX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Scorpius Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Scorpius Holdings
Historical stock prices
Current Share PriceUS$0.16
52 Week HighUS$0.89
52 Week LowUS$0.14
Beta0.12
1 Month Change-46.80%
3 Month Change-66.64%
1 Year Change-80.50%
3 Year Change-97.75%
5 Year Change-98.10%
Change since IPO-99.98%

Recent News & Updates

Recent updates

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Dec 28
Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Sep 02
Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics names Anthony Manning as chief scientific advisor

May 10

Heat Biologics EPS misses by $0.01, misses on revenue

May 05

We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely

Apr 30
We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Mar 07
Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Jan 13
Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics signs a licensing agreement; Appoints new CFO

Jan 06

Heat Biologics soars 14% on completion of ZVX-60 vaccine cell line for COVID-19

Dec 16

Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Zoomed 124% In The Last Year

Nov 20
Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Zoomed 124% In The Last Year

Heat Biologics Provides Update, And Other News: The Good, Bad And Ugly Of Biopharma

Nov 02

Shareholder Returns

SCPXUS BiotechsUS Market
7D-1.9%0.9%0.4%
1Y-80.5%10.3%28.8%

Return vs Industry: SCPX underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: SCPX underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is SCPX's price volatile compared to industry and market?
SCPX volatility
SCPX Average Weekly Movement17.5%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: SCPX's share price has been volatile over the past 3 months.

Volatility Over Time: SCPX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200877Jeff Wolfhttps://www.scorpiusbiologics.com

Scorpius Holdings Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company provides analytical testing, downstream process development, formulation optimization and development, and clinical biomanufacturing services to pharmaceutical and biotech companies. It is also involved in the provision of pre-clinical and product development; chemistry, manufacturing, and control analytical support; and bioassays.

Scorpius Holdings, Inc. Fundamentals Summary

How do Scorpius Holdings's earnings and revenue compare to its market cap?
SCPX fundamental statistics
Market capUS$5.90m
Earnings (TTM)-US$53.05m
Revenue (TTM)US$8.24m

0.7x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SCPX income statement (TTM)
RevenueUS$8.24m
Cost of RevenueUS$34.67m
Gross Profit-US$26.43m
Other ExpensesUS$26.62m
Earnings-US$53.05m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Mar 28, 2024

Earnings per share (EPS)-1.47
Gross Margin-320.76%
Net Profit Margin-643.86%
Debt/Equity Ratio0%

How did SCPX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.